PDSB: PDS Biotechnology Company Buyout Price

The PDS Biotechnology (PDSB) price chart demonstrates the business valuation, which currently stands at 110.59. The company develops cancer-fighting agents, leveraging the macro-stability of a scientific niche that remains independent of economic cycles. Effective management minimizes research risks by expanding partnerships, enabling the successful advancement of late-stage drug trials in collaboration with leading US oncology centers.

PDSB (PDS Biotechnology Corporation) Total Company Value history from 11/23/2025 to 10/27/2026

PDS Biotechnology Corporation - analytical breakdowns and key metrics (PDSB)

- price and consensus price forecast:

Share Price PDS Biotech|PDSB - Price Target Chart

- market capitalization data:

Market Capitalization PDS Biotechnology|PDSB - Enterprise Value

- book capitalization data:

Net Assets per Single Share PDS Biotechnology|PDSB - Company Book Value|Market-to-Book Ratio pdsbiotech.com|PDSB - Aggregate Company Assets

- debt and liquidity data:

Debt to Equity Ratio PDS Biotechnology|PDSB - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio PDS Biotech|PDSB - Company Debts|Debts to Book Value PDS Biotechnology

Fundamental valuation:PDS Biotechnology (PDSB)

Original product of PDS Biotechnology Corp

PDS Biotechnology is developing a diversified immunological platform to combat oncology and infections. Pipeline diversification is reflected in the capital structure, where market value is adjusted for net debt. This metric determines the actual cost of a full business buyout, accounting for available cash. An analysis of the company's total market valuation on GURU.Markets allows for the identification of overpayment for scalability potential. The dynamics of this indicator serve as a marker of the asset's fundamental value.

Competitors of PDS Biotechnology (PDSB)

ImmunityBio Inc - Business Value|Total Company Value IMCR (Immunocore PLC)|JANX - Company Buyout Price|Arcus Biosciences, Inc. (RCUS) - Enterprise Value|ZYME (zymeworks.com) - Total Company Value|Total Company Value TNGX (Tango Therapeutics, Inc.)|Total Enterprise Value IOVA|Total Company Value Immatics Corp IMTX|Business Value Xencor Inc. (XNCR)|Compass Therapeutics - Enterprise Value|replimune.com - Real Price to Acquire Entire Company|LYEL (Lyell Immunopharma, Inc.) - Total Company Value|IPHA: Total Enterprise Value|pyxisoncology.com (PYXS) - Total Company Value|CGEN (Compugen) - Total Company Value|Total Company Value IOBT (IO Biotech, Inc.)|Total Enterprise Value sutrobio.com|INKT: Enterprise Value|Full Takeover Company Value werewolftx.com HOWL|IMMX: Real Price to Acquire Entire Company|ALXO - Total Enterprise Value|Real Price to Acquire Entire Company Cue Biopharma, Inc. (CUE)|SONN - Value Adjusted for Debt and Cash|MAIA Biotechnology, Inc. - Enterprise Value|LIMN (Liminatus Pharma Inc.) - Company Buyout Price|Total Company Value LVTX|Real Price to Acquire Entire Company NXTC|Total Company Value LPTX (Leap Therapeutics, Inc.)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Real Price to Acquire Entire Company SNSE (Sensei Biotherapeutics, Inc.)|Theriva Biologics Inc - Enterprise Value|Gritstone Bio (GRTS) - Total Company Value|KA: Business Value|Total Company Value NEXI|Total Enterprise Value Turnstone Biologics Corp.|Vaccinex - Real Price to Acquire Entire Company|Full Takeover Company Value Harpoon Therapeutics Inc (HARP)